Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Pathobiology 2026

Pathobiology 2026 – May 16-19, 2026, in Fort Myers, Florida. Similar to the past two Annual Meetings, Pathobiology 2026 will be a stand-alone meeting that will leverage our society’s unique strengths in the understanding of cellular and molecular...

Neurocritical care leaders will discuss NPi pupillometry in NeurOptics sessions at AACN NTI 2026.

CCRN, CNRN, SCRN, FAHA, FNCS, FCCM, will speak as part of NeurOptics' in-booth clinical education programming at AACN NTI 2026, May 17–20, in San Diego. NeurOptics will be exhibiting in Booth #1616. Olson will present "Evidence-Based Practice in...

SUANNUTRA USA secures U.S. distribution rights for TetraSOD.

safeguarded by 10 patents and backed by 17 peer-reviewed studies conducted since 2006, with the latest published in March 2026. Its efficacy at a daily dose of just 25 mg has been demonstrated in multiple human clinical trials, highlighting its...

MinuteClinic highlights improved access and outcomes through its clinically supervised weight-loss program

its clinically supervised weight-loss program to support earlier intervention and more accessible preventive care. As of 2026, the program has demonstrated strong outcomes: 85% of patients lost weight within their first three months About...

Avenacy Announces U.S. Launch of Ready-to-Use Tranexamic Acid in 0.7% Sodium Chloride Injection

standards. U.S. sales of Tranexamic Acid Injection were approximately $30.2 million for the twelve months ending in March 2026, with ready-to-use presentations accounting for approximately $15 million of total sales.1 Indications Tranexamic Acid...

2nd Annual MaxPotent Pharma Summit 2026

2nd Annual MaxPotent Pharma Summit – a leading international platform bringing together senior executives, regulatory authorities, technology providers, and pharmaceutical innovators dedicated to advancing the future of Highly Potent Active...

Novo Nordisk’s Ozempic pill—the only FDA-approved oral peptide GLP-1 for adults with Type 2 Diabetes—will soon be available in the U.S

(semaglutide) tablets 25 mg for use in adults with type 2 diabetes. The company expects an FDA decision by the end of 2026. Do not use Ozempic® if: you or any of your family have ever had MTC, or if you have an endocrine system condition called...

UCB to acquire Candid Therapeutics, strengthening its immunology pipeline with novel T-cell engagers

including required anti-trust clearance and other customary conditions, and is expected to close by end of Q2 – early Q3 2026. Lazard is acting as financial advisor to UCB, and Covington & Burling LLP is serving as legal counsel to UCB. Jefferies...

TIME names Sprout Pharmaceuticals, the maker of Addyi (flibanserin), among the 10 most influential health and life science companies of 2026

Industry Leaders will be available on newsstands April 28. The full list is available now at: https://time.com/article/2026/04/27/time100-companies-health/ About Sprout Pharmaceuticals Sprout Pharmaceuticals is leading a revolution in women's...

Rapid Nexus Secures VA and DoD Contracts, Launches Commercial Deployment of FDA-Cleared Wound Technology

of Defense (DoD) and will begin commercial deployment of its FDA-cleared wound treatment, Hemastyl®, starting May 1, 2026. Clinical training across VA and DoD facilities will begin May 1, marking the company's first large-scale entry into...

Apertura Gene Therapy and Broad Institute scientists share data on TfR1 CapX™, a novel CNS-targeting capsid

and spinal cord, at the 29th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), held May 11–15, 2026 in Boston, MA. Data presented by Apertura at ASGCT show that TfR1 CapX can be manufactured at clinically relevant scale,...

Mundipharma reports positive Phase III ReSPECT results for REZZAYO® (rezafungin) in preventing invasive fungal diseases in stem cell transplant patients

New Drug Application (sNDA) to the FDA in 2H26 based on the ReSPECT results. Mundipharma expects an EMA submission in Q3, 2026. About rezafungin Rezafungin is a next-generation echinocandin approved for the treatment of candidaemia and invasive...

Ascletis announces completion of enrollment in its U.S. Phase II study evaluating ASC30, an oral small-molecule GLP-1R agonist, for diabetes treatment

indication of obesity. Topline data from the Phase II study for the treatment of T2D are expected in the third quarter of 2026. "ASC30 has potential to be the best-in-class oral small molecule GLP-1 for obesity, evidenced by its efficacy and...

OrthoTrophix reports new findings on TPX-100, revealing a structural relationship between femoral bone shape and meniscal pathology in knee osteoarthritis

with Attenuation in IA TPX-100 Treated Knees" (Poster #665) at the Osteoarthritis Research Society International (OARSI) 2026 World Congress in West Palm Beach, Florida (23 – 26 April 2026). The poster is being presented April 24 – 25. WORMS (Whole...

“O’Shaughnessy Ventures supports scientist uncovering biology’s hidden communication system

up to $100,000 and gain access to OSV's network of founders, investors and experts. OSV will award up to 20 fellowships in 2026. Mitchell-Wang is the fourth fellow announced in 2026. More information about previous fellows is available at OSV's...

Bristol Myers Squibb and Pfizer to provide Eliquis® (apixaban) through the Mark Cuban Cost Plus Drug Company

the layers that drive up costs, you give people more control over how they get their prescriptions.” Beginning April 27, 2026, Eliquis will be available on Cost Plus Drugs, and patients with a prescription will pay a total of $345 for a 30-day...

CRENESSITY® lowers glucocorticoid doses while maintaining androgen control in adults with classic congenital adrenal hyperplasia

build upon previously reported one-year results and were presented at the American Association of Clinical Endocrinology 2026 Annual Meeting in Las Vegas. Chronic exposure to supraphysiologic GC doses is associated with cardiometabolic...

Orthogon Therapeutics Raises an Additional $11M Financing for Its BK Virus Antiviral Drug Program

that has eluded the field for decades. The program will be featured at leading transplant and virology meetings in 2026, building on findings presented at the ASN in 2025. Alongside its core focus on polyomaviruses, Orthogon is advancing programs...

Recent Innovations Showcased by Baxter

time spent in the operating room. The AAT XR is expected to be available in the United States early in the second half of 2026, with select geographic expansion planned later this year. The Dynamo Series smart stretcher, the latest innovation in...

13th Int'l Conference on Chemical and Biological Sciences 2026

13th International Conference on Chemical and Biological Sciences (ICCBS 2026) will be held in Osaka, Japan during, co-sponsored by Network Joint Research Center for Materials and Devices: Dynamic Alliance for Open Innovation Bridging Human,...

Results 41 - 60 of 95